Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients
- 28 May 2015
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 152 (1), 67-76
- https://doi.org/10.1007/s10549-015-3437-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- A Review of the Cardiovascular Effects of Oncology AgentsJournal of Pharmacy Practice, 2008
- Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and managementExpert Opinion on Pharmacotherapy, 2007
- Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 TrialJournal of Clinical Oncology, 2006
- Stratified false discovery control for large‐scale hypothesis testing with application to genome‐wide association studiesGenetic Epidemiology, 2006
- NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced CardiotoxicityCirculation, 2005
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992